



*the pharma-focused accelerator for digital health startups*

## **PharmStars 2021 Fall Startups**

Confidential - Do Not Distribute

### **Droice Labs- *RWE from EMR and Patient Data* (New York, NY)**

[www.droicelabs.com](http://www.droicelabs.com)

*Mayur Saxena, CEO* - mayur@droicelabs.com

*Tasha Nagamine, CAIO* - tasha@droicelabs.com

Real-world evidence is critical for pharma decision making in drug development, payor negotiations, and quantifying unmet patient needs. Each source of real-world patient data has its own format, noise, bias, and nuance and when not combined properly results in low quality, low utility data. Droice Lab's platform harmonizes patient data from various sources and generates standardized, accurate, and clinically meaningful patient profiles for evidence generation. Trained and tuned on data from millions of patients, Droice's product has been leveraged by several big pharma companies for evidence generation activities across multiple disease areas including chronic and rare disease.

### **Evocal Health- *Vocal Biomarker for Respiratory and Cardiovascular Health* (Hamburg, Germany)**

[www.evocalhealth.com](http://www.evocalhealth.com)

*Philip Mertes, CEO and Co-founder* - philip.mertes@evocalhealth.com

EVOCAL Health is unlocking the human voice as a biomarker for health. The company's CE-certified, device-agnostic platform enables pharmaceutical companies to collect, monitor, and analyze patient voice data. The vocal biomarker technology provides a comprehensive picture of a patient's disease progression and response to treatment to better understand cardiovascular, respiratory and neurodegenerative or mental diseases in a non-invasive, convenient, and privacy-compliant way. EVOCAL Health's vocal biomarker technology provides longitudinal, real-world evidence, enabling patient risk stratification and predictive disease monitoring.

### **Liyfe- *Oncology Patient Engagement Platform* (New York, NY)**

[www.liyfeclinic.com](http://www.liyfeclinic.com)

*Lily Tang, CEO* - lily@liyfeclinic.com

*Sherry Chen, CTO* - sherry@liyfeclinic.com

Liyfe is the first AI-based digital nurse, enabling symptom and risk assessment for oncology and NASH patients. Using this tool, patients can understand the severity of their symptoms while data on potential risks and complications are communicated to the clinical care team in real time. The Liyfe digital nurse can be used to improve patient quality of life and outcomes, increase adherence and persistence, reduce ER visits and hospitalization, and reduce on-site

monitoring needs and cost, while providing valuable longitudinal real-world data (RWD) in clinical trials as well as for marketed products.

**Longenesis- *Participant Identification/ Management for Study Preparation* (Riga, Latvia)**

[www.longenesis.com](http://www.longenesis.com)

*Sergey Jakimovs, CEO - sj@longenesis.com*

*Emil Syundyukov, CTO - es@longenesis.com*

The Longenesis platform enables efficient participant identification and engagement for clinical studies. Study sponsors can compliantly browse in real-time through more than 1 million patient records from over 30 participating clinics, patient advocacy groups, and biobanks in the EU and MENA, resulting in a 70% reduction in time and cost. Additionally, the Longenesis companion solution drives dynamic consent management and instant, on-demand participant engagement for the collection of clinical, real-world evidence and quality of life measures, thus offering seamless participant management in the preparation of clinical studies.

**Neucruit- *Novel Patient Recruitment* (London, England)**

[www.neucruit.com](http://www.neucruit.com)

*Livia Ng, CEO - livia@neucruit.com*

Neucruit helps sponsors, CROs, and investigators go beyond traditional recruitment avenues to reduce barriers and accelerate enrolment for their clinical trials. The Neucruit intelligent algorithms engage cohorts of potential participants from online conversations across dozens of platforms including Facebook, Twitter and Reddit. The platform improves accessibility for more remote and diverse patient populations, reducing site burden and de-risking clinical trial recruitment.

**Nori Health- *IBD Patient Engagement Platform* (Amsterdam, Netherlands)**

[www.norihealth.com](http://www.norihealth.com)

*Roeland Pater, CEO - roeland@norihealth.com*

*Dandyano Zentveld, COO - dandyano@norihealth.com*

The Nori Health CE-approved digital therapy app supports IBD (Crohn's and Colitis) patient management of behavioral and psychological factors that contribute to medication non-adherence and sub-optimal quality of life. During their six-week program, patients chat with a digital coach to share their experiences and gain insights into disease management, all while Real World Data is captured. Nori Health's product utilizes education, behavioral intervention, and cognitive behavioral therapy and is under development for additional disease areas.

**nQ Medical- *Cognitive Digital Biomarker* (Cambridge, MA)**

[www.nq-medical.com](http://www.nq-medical.com)

*Richie Bavasso, CEO* - bavasso@nq-medical.com

*Sri Mruthik, CTO* - mruthik@nq-medical.com

This FDA Breakthrough designated medical device is a digital biomarker for cognition and motor disorders. Through AI-aided analysis of personal device interactions, this device passively collects and analyzes data on HOW people interact with their personal devices from home. Pharma can use this device across a wide variety of diseases to develop meaningful digital endpoints for early detection, disease progression monitoring, and measuring the impact of therapeutic compounds to support pipeline development, decrease trial costs, and expedite time to market.

**Prism Analytic Technologies- *Analytic and Visualization of Trial Design Data* (Cambridge, MA)**

[www.prism.bio](http://www.prism.bio)

*Brendan Guerin, Co-founder and CEO* - brendan@prism.bio

*Maria Dellapina, Head of Operations* - maria@prism.bio

Prism's data analytics platform unlocks crucial insights hidden within messy, unstructured data silos such as public trial registries, literature, vendor datasets, and internal documents. The platform rapidly transforms untidy trial-level data into neat, cleanly-categorized datasets that are analyzed and visualized within the customizable, real-time dashboards. Prism has successfully applied this flexible, secure platform to multiple use cases, including clinical trial design, market analyses, and research synthesis. With Prism, clients save countless hours of manual processing time, maximize the value of existing resources, and are empowered to make evidence-based decisions every day.

**Seascope Clinical- *Clinical Operations Management Platform* (Redwood City, CA)**

[www.seascopeclinical.com](http://www.seascopeclinical.com)

*Monica Roy, CEO* - monica@seascopeclinical.com

*Josett McKoy, Marketing Director* - josssett@seascopeclinical.com

Built by clinical operations experts, Seascope's clinical operations oversight solution is a software platform that quickly provides insights on clinical trial performance at the macro and micro levels. The Seascope Clinical platform improves team and study efficiency by eliminating repetitive manual tasks including data lookup and cross-referencing between excel spreadsheets, trial management systems and other data sources. Clinical operations teams can collaborate, make and communicate decisions, prioritize tasks, and mitigate risks from a single source of consolidated data displayed in simple, clear, and actionable formats.

**SmartTab- Novel Drug Delivery Platform (Denver, CO)**

[www.smarttab.co](http://www.smarttab.co)

*Robert (Bob) Niichel, Founder/CEO - robert.niichel@velocedigital.com*

*Sacha Francois Heppell, Chief Marketing Officer - sacha.heppell@velocedigital.com*

SmartTab is developing an advanced platform of ingestible capsules to deliver biologics and targeted medications, offering pharmaceutical companies improved product efficacy, novel administration routes, and patent extension opportunities. The SmartTab platform delivers the correct dosages at the appropriate time to targeted locations in the gastrointestinal tract and is intended to replace both traditional coated capsules and injections. SmartTab has completed proof-of-concept pre-clinical studies and is in the process of submitting to the FDA through the 510(k) process.

**Tag.bio- Data Analytics Platform for Disparate Internal Sources (San Francisco, CA)**

[www.tag.bio](http://www.tag.bio)

*Tom Covington, CEO - tom@tag.bio*

*Mark Mooney, VP Customer - mark@tag.bio*

Tag.bio accelerates the drug development process by reducing the time and effort required to manage and analyze data. Data is harmonized to create a catalogue of self-service data products spanning discovery, clinical trials, and real-world evidence. The Tag.bio platform enables pharmaceutical companies to analyze harmonized data in seconds, accelerating data-driven decisions, reducing time to publication, and minimizing the cost of curiosity-driven discovery. With deployments at several major pharmaceutical companies, and leveraged across the full range of drug development, their product makes data accessible and usable to both scientists and data scientists.

**The Clinician- Decentralized Clinical Trial Management (Auckland, New Zealand)**

[www.theclinician.com](http://www.theclinician.com)

*Ron Tenenbaum, CEO - rt@theclinician.com*

*Tamaryn Hankinson, Managing Director - tam@theclinician.com*

The Clinician helps clinical trial sponsors run effective, decentralized trials by enabling real-time access to patient-generated data, while their engaging, educational, digital experience for patients drives better recruitment and retention. Using bi-directional patient communication and engagement, their solution also collects subjective measures (patient reported outcome measures (PROMs) & electronic Clinical Outcome Assessments (eCOA)) from patients in unsupervised environments, turning them into objective, quantified measures. Data is visualized in dashboards at both the individual and population level and is instantly actionable, triggering both alerts when patients are at risk as well as clinician workflows to adjust dosing or address tolerability. Selected for its exceptional engagement rates, security, and scalability, the Singaporean Ministry of Health, Israel's Clalit and top 10 pharma companies have used The Clinician's solution to power over 1000 projects.